Revenue since approval for select cancer drugs 2017
This statistic shows the total revenue since approval for select cancer drugs that were on the market as of 2017. As of that year, Alexion Pharmaceuticals' drug Eculizumab generated a total revenue of nearly 13 billion U.S. dollars since the drug's approval in March 2007.